Internal Medicine · Los Angeles, CA
NPI
1114111283
Since 2007
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
10945 Le Conte Ave, Suite 2339
Los Angeles, CA, 90095
Phone (310) 825-6301
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$1.7M
2,553 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Paul Liu prescribed most often to Medicare patients was Prednisone, with 582 prescriptions and refills. In total Paul Liu wrote 2,553 Medicare prescriptions that cost $1.7M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-11-01.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Prednisone Generic | 582 | 1,493 | 191 | $8,551 |
| Methotrexate Methotrexate Sodium | 445 | 1,235 | 151 | $8,539 |
| Hydroxychloroquine Sulfate Generic | 341 | 1,101 | 131 | $13K |
| Amjevita(Cf) Autoinjector Adalimumab-Atto | 108 | 159 | 21 | $141K |
| Leflunomide Generic | 94 | 297 | 42 | $2,928 |
| Enbrel Sureclick Etanercept | 92 | 98 | 11 | $486K |
| Rasuvo Methotrexate/Pf | 78 | 134 | 22 | $54K |
| Sulfasalazine Generic | 76 | 218 | 32 | $4,253 |
| Allopurinol Generic | 52 | 165 | 25 | $692 |
| Cevimeline Hcl Generic | 45 | 118 | 16 | $9,061 |
| Pilocarpine Hcl Generic | 42 | 114 | 16 | $3,383 |
| Amjevita(Cf) Adalimumab-Atto | 41 | 50 | Under 11 | $61K |
| Meloxicam Generic | 38 | 74 | 20 | $301 |
| Enbrel Etanercept | 37 | 42 | Under 11 | $181K |
| Colchicine Generic | 37 | 61 | 12 | $666 |
Brand drugs: 643 claims; generic drugs: 1,910 claims; opioid claims: 26.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Paul Liu were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.